Medtronic said that this acquisition adds two technologies to its transcatheter valve portfolio: a minimally invasive, surgical transapical technology and a next generation percutaneous, transfemoral technology. These complementary technologies offer compelling clinical benefit to distinctly different subsets of patients with aortic stenosis who are at high or prohibitive risk for surgery, added Medtronic.
Bill Hawkins, chairman and CEO of Medtronic, said: “The combination of Ventor Technologies and our strengths in R&D, operations, medical education and market development will improve patient outcomes and expand physician adoption among both surgeons and interventional cardiologists.”